Revenue ($USD) : $2,073,500,000
R&D spend : $92,000,000.00
Employees : 10,000
Fiscal year end : 12/31/22
CEO : Karim Bitar, CEO

Convatec provides technology for advanced wound care, ostomy care, continence and critical care and infusion care. It offers design and manufacturing services for infusion set technologies and insertion devices for insulin pump treatment.

Convatec announced in May that it partnered with Beta Bionics on the launch of the FDA-cleared iLet Bionic Pancreas for automated insulin delivery. The Beta Bionics iLet uses its inset and contact detach infusion sets for subcutaneous insulin administration. –SW and CN